Skip to content

Clinical trials

Myelodysplastic Syndromes trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelodysplastic Syndromes Country / region: United Kingdom Clear all

110 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20032
20041
20057
20062
20075
20083
20094
20104
20112
20134
201411
20157
20168
20175
20182
20194
20207
20217
20227
20232
20243
20253
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed54
Terminated19
Recruiting13
Unknown status13
Active, not recruiting7
Withdrawn2
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Celgene13
Novartis Pharmaceuticals10
Kiadis Pharma5
King's College Hospital NHS Trust5
European Organisation for Research and Treatment of Cancer - EORTC3
GlaxoSmithKline3
Janssen Research & Development, LLC3
Pfizer3
Takeda3
University College, London3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelodysplastic Syndromes110
Leukemia, Myeloid, Acute59
Leukemia22
Leukemia, Myelomonocytic, Chronic21
Precursor Cell Lymphoblastic Leukemia-Lymphoma16
Hematologic Neoplasms12
Anemia, Refractory, with Excess of Blasts11
Anemia10
Myeloproliferative Disorders9
Graft vs Host Disease8

Trials

Showing 1 to 25 of 110. Each trial links to its page on Pharma Observatory.

10 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.